Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Clinical trial NCT04999800 · UNKNOWN

Trial details

NCT number: NCT04999800
Sponsor: Shi Yuankai
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma

Start date: 2021-07-18
Primary completion: 2023-01-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.